The resulting ease of uncertainty could lead to a rerating of shares.
Given that Bristol Myers Squibb's growth portfolio is already offsetting legacy drug sales, this stock currently has a payout ratio of less than 40%, strongly suggesting the dividend remains safe in the near term.
The 10 stocks that made the cut could produce monster returns in the coming years.
The Motley Fool has a disclosure policy .